A pilot study of L-methionine for the treatment of AIDS-associated myelopathy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 9674817.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The pathogenesis of AIDS-associated vacuolar myelopathy (VM) may be related to abnormality of transmethylation mechanisms in the nervous system. To evaluate the safety and potential efficacy of the methyl-group donor L-methionine in AIDS-associated VM, we conducted a pilot clinical trial in 12 patients with VM. Seven of the nine patients who completed the study had clinical and electrophysiologic improvement. Controlled studies may be indicated to assess the efficacy and safety of L-methionine in AIDS-associated VM.
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Metabolic Diseases
- Methionine
- Spinal Cord Diseases